Should You Buy AstraZeneca plc, Mondi Plc & Hogg Robinson Group plc Today?

Royston Wild takes a look at London giants AstraZeneca plc (LON: AZN), Mondi Plc (LON: MNDI) and Hogg Robinson Group plc (LON: HRG).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am running the rule over three FTSE-listed beauties.

The perfect package

Packaging play Mondi (LSE: MNDI) greeted the market with bubbly financial numbers in Tuesday trade, sending the stock 0.5% higher from last night’s close.

Mondi advised that underlying operating profit for 2015 should clock in above the €767m recorded in the prior period, with underlying earnings per share anticipated to advance between 22% and 27% from 2014 levels, at 131-136 euro cents per share.

And I believe the Surrey business is in great shape to enjoy further stunning earnings growth well into the future, as expansion into hot sub-segments in the packaging industry — not to mention rising presence in the US and Asia — pays off.

The City expects Mondi to report a 10% earnings advance in 2016, resulting in a very-decent P/E multiple of 14.1 times. And a handy 41.5p per share dividend, yielding a chunky 2.8%, seals in the investment case in my opinion.

Services play on the up

Like Mondi, corporate services provider Hogg Robinson (LSE: HRG) also provided plenty of cheer in Tuesday’s session after releasing its own reassuring trading update. Shares were last 2.3% higher as a result.

Hogg Robinson advised that it had “continued to trade in line with our expectations during the second half of the company’s financial year to date,” with full-year growth expected to meet current market expectations. And the growing popularity of cutting-edge products, like its travel and expense management solution Fraedom, should keep earnings heading higher in the longer-term, in my opinion.

The number crunchers expect Hogg Robinson to follow a 6% earnings uptick in the period to March 2016,with a 7% advance in the following year, resulting in ultra-low P/E ratings of 10.4 times and 9.8 times respectively.

And when you throw in prospective dividends of 2.5p per share for 2016 and 2.7p for next year — payouts that yield 3.4% and 3.7% correspondingly — I reckon Hogg Robinson is a terrific selection for those seeking brilliant all-round value.

A premier pills pick

Drugs colossus AstraZeneca (LSE: AZN) has enjoyed a solid bump higher during the past week, with its share price gaining 7% from recent two-year nadirs as bargain hunters have piled in.

And with good reason, in my opinion. AstraZeneca’s advice this month that it expects further revenues falls in 2016 may have weeded out less-hardy investors, but this was always likely to be the case as patent losses on key products like Crestor and Nexium continue.

Instead, I believe the result of chief executive Pascal Soriot’s R&D overhaul in recent years should deliver delicious returns in the years ahead. A focus on ‘growth platforms’ like diabetes, respiratory and oncology is already delivering the goods, with sales in these areas rising 11% in 2015. And I reckon prolonged sales growth can be expected as global healthcare demand takes off.

Although the City expects AstraZeneca to endure a further 10% earnings decline in 2016, I believe a subsequent P/E multiple of 16.5 times is a great level to tap into the firm’s great growth prospects. On top of this, a projected 280-US-cent-per-share dividend yields a splendid 4.2%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£5,000 of 9.2%-yielding Legal & General shares could make me £599 a month in passive income over time!

Legal and General shares remain a top passive income stock in my core portfolio holdings, with a 9.2% yield and…

Read more »

Investing Articles

With a 10.4% yield, P/E ratio of 9.9, and a P/B of 0.37, is this FTSE 100 stock a no-brainer buy for me?

Using a range of popular valuation measures, this FTSE 100 stock appears to offer tremendous value for money. So is…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Down nearly 18% from its 52-week high, is the Lloyds share price now a screaming buy for me?

In recent weeks, the Lloyds share price has under-performed the wider market. Could this be the buying opportunity that I’m…

Read more »

Investing Articles

As BAE Systems’ share price drops 14% should I buy more?

FTSE 100 defence giant BAE Systems recently reiterated strong growth guidance, leaving its share price looking significantly undervalued to me.

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After an 18% jump on its 2024 results, is it too late for me to consider buying this FTSE 100 hidden gem?

This FTSE 100 technology firm unveiled very strong 2024 results recently and a big share buyback, but is it too…

Read more »

Investing Articles

£5,000 invested in Rolls-Royce shares in 2023 would have made this much by now

Rolls-Royce shares have been one of the best-performing UK FTSE 100 investments over the last two years. But how much…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

£5,000 invested in Lloyds shares in 2023 would be worth this much now

Lloyds shares and other banking stocks have thrived in 2024, but has it been a good investment for shareholders who…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Why are investors blowing a raspberry at this FTSE 250 stock?

After a successful IPO, the share price of this FTSE 250 stock's fallen. Our writer looks at the reasons and…

Read more »